The points raised have broad oncology appeal as well as highlighting market access issues which have relevancy for rapidly evolving landscapes.
Key emerging trends on market access
How agencies are approaching assessments for melanoma, lung cancer and RCC
Specific review of PD-1 testing in health technology assessments
Explore the move in the treatment towards combination therapies
Duration: 45 minutes. Available to watch on demand.
Ideal viewing: Global, regional, and affiliate market access and HEOR teams involved in pricing strategy and pricing and reimbursement decisions can benefit from watching this on-demand webinar. Please share this with your colleagues.
Market access for PD-1 inhibitors: where are we now?
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.